Zach Lahn’s FirmTech ‘Not a Sex Toy’ Claim Undercut by Blog

The intersection of private equity, medical technology, and political optics has created a significant hurdle for Iowa gubernatorial candidate Zach Lahn. At the center of the controversy is a $1 million investment Lahn made in 2021 into FirmTech, a company specializing in health-monitoring hardware for men. As Lahn pursues the state’s highest office, his characterization of the company’s product line—which he insists consists strictly of "grade two medical devices"—has clashed with the company’s own historical marketing and industry recognition. The discrepancy has prompted questions regarding transparency and the candidate’s professional background as he faces Democratic challenger Rob Sand in the upcoming November election.

A Chronology of Investment and Governance

The relationship between Lahn and FirmTech began in 2020, when he joined the company’s board of directors. The following year, on September 14, 2021, Lahn deepened his involvement by funneling $1 million into the enterprise through his wholly owned investment firm, Selah Group LLC. This transaction secured 1,250 shares, granting Lahn a 28.2 percent equity stake, effectively making him the second-largest shareholder in the company.

According to campaign officials, Lahn served on the board for three years before resigning in September 2023. The campaign has argued that his departure was prompted by strategic disagreements regarding the company’s marketing direction and overall corporate trajectory. Furthermore, the campaign contends that Lahn exited the firm before the company expanded into the broader, more overt "pleasure product" market. However, public records and archived digital footprints suggest that the marketing language used by the company during Lahn’s tenure was far more fluid than the candidate’s current, rigid definition of the products.

The Marketing Discrepancy

The core of the political friction lies in the terminology used to describe the MaxPR and Tech Ring, two of FirmTech’s flagship products. While Lahn now emphasizes their utility as diagnostic tools for urologists to monitor nocturnal erections, the company has historically utilized terminology that bridges the gap between medical wellness and recreational use.

Archived web data indicates that as recently as June 2022, a blog post on the official FirmTech website explicitly stated, "Cock rings are sex toys which are worn by men and people with penises." This admission appeared while Lahn was an active member of the board. Subsequent entries in the company’s blog archive further complicate Lahn’s narrative. In January 2023, the company proudly announced that the Tech Ring had been awarded "Most Innovative Sex Toy of the Year" by XBIZ, a trade publication covering the adult industry. While the company now claims such labels are "inaccurate and shallow," the public record demonstrates that these descriptors were used to market the brand for years.

The issue is further exacerbated by the fact that some of these descriptors remain active. A post published in June 2026, long after Lahn’s stated resignation, continues to promote the Max Performance Ring as "the go-to male sex toy for enhancing sexual performance."

Medical Utility vs. Consumer Labeling

To understand the tension, one must look at the dual nature of "sextech." FirmTech, founded by Dr. Elliot Justin and Dr. James Hotaling, occupies a unique niche. Their hardware is designed to collect data that can be interpreted by urologists to diagnose erectile dysfunction (ED), a condition affecting millions of men globally. In this context, the devices function as medical instruments.

However, the industry standard for these devices often necessitates marketing to the consumer market, where the terminology of "sex toys" is widely understood and commercially viable. Dr. Justin has been vocal in his defense, arguing that the "sex toy" label is a misnomer that could hinder the medical adoption of the technology. "If you claim that we are a ‘sex toy’ company, we will seek correction and if necessary take legal action," Justin stated in a recent interview. He argues that the stigma associated with the term "toy" interferes with the clinical perception of a device that is, in reality, providing diagnostic data to help treat a common medical condition.

The Political and Ethical Implications

For voters, the question is not necessarily about the efficacy of the product, but about the transparency of the candidate. The Bulwark, which first brought significant attention to this discrepancy, noted that the central issue is whether Lahn has been forthcoming about his business history.

In the modern political landscape, the branding of a product often carries as much weight as its technical specifications. Lahn’s attempt to retroactively sanitize his investment by emphasizing the "grade two medical device" classification may be viewed by critics as an attempt to distance himself from an industry that remains politically sensitive. His political opponents argue that a candidate’s business history is a window into their judgment and honesty. If Lahn was comfortable with the company’s branding while he served on the board, his current pivot is being framed by some as a calculated move to avoid backlash from conservative voters.

Broader Context of Sextech in Public Discourse

The friction surrounding Lahn’s investment occurs within a wider, global debate regarding how society classifies sexual health products. In the United Kingdom, the recent introduction of sex education initiatives in Parliament has triggered intense debate, with some politicians embracing the discourse and others using it as a weapon to disparage political rivals. The remark by Conservative leader Kemi Badenoch, who linked the display of sex toys in Parliament to "fiddling while Rome burns," illustrates the potent political baggage these products carry.

This cultural resistance is precisely why Lahn’s team is working to distance the candidate from the "sex toy" label. In the context of an Iowa gubernatorial race, where social issues are often at the forefront of the campaign trail, the optics of being a major investor in the sex-wellness industry are fraught with risk. The challenge for Lahn is that the internet, through the permanence of archives and digital caches, makes it difficult to rebrand his past involvement.

Conclusion and Future Outlook

As the November 3 election approaches, the pressure on Lahn to address these inconsistencies is unlikely to subside. His Democratic challenger, Rob Sand, has already begun to capitalize on the narrative, positioning the debate as a matter of integrity.

While the debate over terminology—whether a device is a "medical tool" or a "sex toy"—may seem semantic to some, it touches on the fundamental requirement of political accountability. A candidate’s professional history is a primary metric for voters. Whether Lahn can successfully separate his financial interests from the evolving public perception of his former company remains to be seen. For now, the archived blog posts and the record of his tenure on the board stand as a permanent counter-narrative to his campaign’s current messaging. The case of FirmTech serves as a reminder that in the digital age, private sector investments can quickly become public liabilities, especially when they involve products that sit at the intersection of medical science and societal taboo.